Oligoribonucleotide derivatives for specific inhibition of gene expression

US7635769B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Eugen Uhlmann · Königstein, DE
• Jochen Huber · Mittelbiberach, DE
• Niki Gunkel · Heidelberg, DE
• Sandra Neumann · Offenbach, DE

Key dates

• Filing date: Sep 22, 2005
• Grant date: Dec 22, 2009
• Expiry date: Jan 15, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/321
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to oligoribonucleotide derivatives which have a 2′5′-linked oligoribonucleotide residue without a 5′-phosphate residue on the 3′ end and to the use thereof for specific inhibition of gene expression.